Last updated: April 29, 2026
Ozemback is independent journalism and educational reporting on a fast-moving medical landscape. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Peptides and several drugs we cover are investigational, off-label, or not FDA-approved for the uses discussed. Read this page in full before acting on anything you find here.
All content on ozemback.com — including the homepage, the free Post-GLP-1 Reset guide, every blog article, every email, every social post, and any future product — is provided for general informational and educational purposes only. It is journalism and editorial commentary, not medical advice.
Nothing on this site is intended to diagnose, treat, cure, mitigate, or prevent any disease, condition, or symptom. The content is not a substitute for professional medical advice, diagnosis, or treatment.
Reading this site, downloading the guide, subscribing to emails, or contacting Ozemback does not create a doctor–patient, clinician–patient, therapist–patient, dietitian–patient, pharmacist–patient, or any other professional relationship. We are writers and editors, not your healthcare team.
Ozemback covers peptides as a journalistic subject because the conversation is happening at scale and deserves honest reporting. Coverage is not a recommendation, endorsement, or facilitation of acquisition or use.
Ozemback covers drugs that are still in trials or used off-label, including retatrutide, orforglipron, cagrisema, and microdosing protocols of approved GLP-1 medications. These are reported as news and as evolving science. Investigational compounds have not completed FDA review and are not available for general prescription. Off-label use is a decision between a patient and a licensed prescriber.
Ozemback discusses Ozempic®, Wegovy®, Mounjaro®, Zepbound®, Rybelsus®, Saxenda®, Victoza®, Trulicity®, and other branded medications for editorial purposes. All trademarks are property of their respective owners — Novo Nordisk A/S, Eli Lilly and Company, and others. Ozemback is not affiliated with, endorsed by, sponsored by, or licensed by any pharmaceutical manufacturer. The name "Ozemback" is editorial commentary on a cultural phenomenon (the post-GLP-1 rebound) and is not used to identify, market, or trade on any specific medication.
Ozemback does not sell medications, peptides, supplements, hormones, injectables, or compounded products of any kind. We do not operate a pharmacy, clinic, telehealth service, or coaching program. Mentions of products, brands, suppliers, clinics, or protocols are editorial and do not constitute endorsement.
If Ozemback ever introduces affiliate links, sponsored content, paid placements, or its own paid products, it will be clearly and prominently disclosed on the relevant page and in this disclaimer. As of the "last updated" date above, Ozemback has no paid product, no affiliate program, and no sponsored content.
Any testimonials, case studies, before/after stories, or composite narratives published by Ozemback represent individual experience under unique circumstances. They are not promises, guarantees, or typical outcomes. Weight loss, weight maintenance, body composition, metabolic, cognitive, recovery, and longevity outcomes vary substantially between individuals and depend on factors outside our knowledge or control.
Statements on this site about peptides, supplements, foods, herbs, lifestyle interventions, and investigational drugs have not been evaluated by the U.S. Food and Drug Administration. These statements and the products or substances they discuss are not intended to diagnose, treat, cure, or prevent any disease.
Ozemback links to studies, news outlets, and third-party resources. We do not control, endorse, or guarantee the accuracy of external content. Following an external link is at your own risk.
Ozemback is an independent editorial project. It is not affiliated with, owned by, controlled by, or operated on behalf of any pharmaceutical company, compounding pharmacy, peptide supplier, telehealth platform, supplement brand, clinic, or healthcare system.
Ozemback is published from the United States. Laws and regulations regarding GLP-1 medications, peptides, supplements, and off-label use vary substantially by country, state, province, and region. Readers outside the United States are responsible for verifying the legal status, availability, and regulatory framework that applies to them.
If you are experiencing a medical emergency — including severe abdominal pain, signs of pancreatitis, persistent vomiting, allergic reaction, suicidal thoughts, severe hypoglycemia, or any acute symptom — call 911 (US) or your local emergency number immediately. Do not rely on this website, the guide, email, or any digital resource in an emergency.
For mental health crisis support in the US, dial 988 (Suicide & Crisis Lifeline).
To the maximum extent permitted by applicable law, Ozemback, its authors, editors, contributors, and affiliates disclaim all liability for any direct, indirect, incidental, consequential, special, exemplary, or punitive damages arising out of or related to your use of this site or any content on it. You use this site, the guide, and any information contained herein at your own risk.
This disclaimer may be updated periodically as the regulatory and scientific landscape evolves. The "Last updated" date at the top reflects the most recent revision. Continued use of the site after an update constitutes acceptance of the revised terms.
Questions about this disclaimer, corrections to editorial content, or legal notices: info@ozemback.com.